Monday, Aug. 19, 2019 Doors open at 5:30 p.m.; program begins at 6 p.m.
The Sebastian – Vail |Vail
Alzheimer’s disease will be one of the greatest public health challenges of the 21st century unless effective interventions are developed. As a result of increasing life expectancy in the Western world and developing countries, the number of elderly people at risk of developing Alzheimer’s disease is growing rapidly and is estimated to reach 115 million in 2050. The oldest, those older than 85, comprise the fastest growing segment of the population with more than 50% suffering from Alzheimer’s disease. It’s now a public health imperative to find pragmatic solutions for the disease and end the suffering of the patients and their families.
Dr. Michal Beeri will discuss how the disease is diagnosed, what are considered “concerning” and “non concerning” memory problems, risk and protective factors for the disease, whether genetics affect the risk of developing Alzheimer’s disease, why the medications we are investigating are not working, the new therapeutic directions the field is taking and how novel technologies may help prevent the disease altogether. Following Dr. Beeri’s presentation, Dr. Samantha Holden of the CU School of Medicine will engage Dr. Beeri in a dialogue exploring the status of the fight against Alzheimer’s.
Prof. Michal Beeri is a recognized world leader in the study of Alzheimer disease. She is the Director of the Joseph Sagol Neuroscience Center at the Sheba Medical Center, Israel and a Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, NY. Dr. Beeri has a BA in psychology and business administration and a direct Ph.D. in clinical psychology, all of which she finished cum laude. She has published over 150 peered reviewed publications, many in journals of the highest impact in the field. Her research has been continuously funded by the National Institutes of Health for over 15 years as well as by other prestigious organizations such as the Alzheimer’s Association. The main focus of her work is identifying factors (such as diabetes and obesity) that are linked to the very earliest signs of cognitive decline, discovering the underlying brain changes that are affected by these factors, and developing interventions targeted at the very earliest stages of the disease, which she views as the optimal window of opportunity to prevent cognitive decline and Alzheimer’s disease.
Dr. Samantha Holden is an Assistant Professor of Neurology at the CU School of Medicine. She is affiliated with both the University of Colorado Movement Disorders Center and the Alzheimer’s Disease Research and Clinical Center. Her interests include conditions that present with symptoms affecting both cognition and movement such as Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease with parkinsonism.
This program is generously underwritten by Dierdra & Ronnie Baker and Bobbie & Jim Ruh. It is sponsored by Vail Health and produced in partnership with B’nai Vail